Journal profile · Pathology
Cancer Cytopathology
ISSN 1934-662X · eISSN 1934-6638 · Wiley-Blackwell · UNITED STATES · Bimonthly
Cancer Cytopathology: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 2.83; hybrid open access; APC about USD 3,000; median 75 days to acceptance (59 articles, last 24 months); community-reported acceptance: about 25%; 101 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Cancer Cytopathology is published by Wiley-Blackwell and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cervical Cancer and HPV Research, Thyroid Cancer Diagnosis and Treatment and Head and Neck Cancer Studies, together about 25.2% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Cancer Cytopathology provides a unique forum for interaction and dissemination of original research and educational information relevant to the practice of cytopathology and its related oncologic disciplines. The journal strives to have a positive effect on cancer prevention, early detection, diagnosis, and cure by the publication of high-quality content. The mission of Cancer Cytopathology is to present and inform readers of new applications, technological advances, cutting-edge research, novel applications of molecular techniques, and relevant review articles related to cytopathology.
From the journal's Aims & Scope
Research area (LetPub): Pathology
Editor-in-chief Celeste N. PowersPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cervical Cancer and HPV ResearchMedicine10.1%
- Thyroid Cancer Diagnosis and TreatmentMedicine9.6%
- Head and Neck Cancer StudiesMedicine5.5%
- Lung Cancer Treatments and MutationsMedicine5.4%
- Salivary Gland Tumors Diagnosis and TreatmentMedicine5.3%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology5.1%
- Lung Cancer Diagnosis and TreatmentMedicine4.9%
- Pancreatic and Hepatic Oncology ResearchMedicine4.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pathology | Zone 2 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 3 |
| Minor | Pathology | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pathology | Zone 2 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of ScienceMEDLINEPubMedEmbaseCASCAB AbstractsCINAHLCurrent ContentsPublisher website
Other: EBSCO, ProQuest
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.83LetPub ·
- CiteScore 2026-06
- 6.1LetPub ·
- SJR 2026-06
- 0.98LetPub ·
- SNIP 2026-06
- 1.22LetPub ·
- h-index
- 45LetPub ·
- h-index
- 86OpenAlex ·
- i10-index
- 972OpenAlex ·
- 2-year mean citedness
- 2.01OpenAlex ·
- Self-citation rate
- 10.3%LetPub ·
- Share of gold OA articles
- 40.56%LetPub ·
Volume
- Articles per year
- 48LetPub ·
Articles by year OpenAlex count · 2,256 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 94 | 47 | 21 |
| 2025 | 101 | 65 | 178 |
| 2024 | 119 | 84 | 431 |
| 2023 | 120 | 102 | 703 |
| 2022 | 145 | 47 | 1,179 |
| 2021 | 131 | 92 | 1,424 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
75 daysMedian, submission to acceptance · P25–P75 55 days – 96 days
- Acceptance to online
- median 36 days (59 articles)
- Submission to online
- median 113 days
- Sample
- 59 articles with submission and acceptance dates (192 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 1 monthLetPub ·
- Average acceptance (community reports)
- 25%LetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,000 / EUR 2,510 / GBP 1,960 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Wiley-Blackwell
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Bimonthly
- ISSN
- 1934-662X
- Electronic ISSN
- 1934-6638
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Cancer Cytopathology
What CAS zone is Cancer Cytopathology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cancer Cytopathology is in Zone 3 of Medicine, and in Zone 2 of the minor category Pathology / Oncology. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cancer Cytopathology?
The latest impact factor listed by LetPub is 2.83; CiteScore 6.1, h-index 86.
How long does peer review take at Cancer Cytopathology?
Based on the dates recorded on 59 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 75 days (interquartile range 55–96 days); authors report an average review time of about 1 month; the community-reported acceptance is “about 25%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Cancer Cytopathology?
According to LetPub and DOAJ records, Cancer Cytopathology is indexed in SCIE and Scopus. The journal's website also lists Web of Science, MEDLINE, PubMed, Embase, CAS, CAB Abstracts, CINAHL and Current Contents; that list has not been checked against each database.
Is Cancer Cytopathology open access, and what is the APC?
Cancer Cytopathology is a hybrid journal. For open-access publication: APC about USD 3,000.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .